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enefit of a 600-mg Loading Dose of Clopidogrel
n Platelet Reactivity and Clinical Outcomes in
atients With Non–ST-Segment Elevation Acute
oronary Syndrome Undergoing Coronary Stenting
homas Cuisset, MD,* Corinne Frere, MD,† Jacques Quilici, MD,*
ierre-Emmanuel Morange, MD, PHD,† Lyassine Nait-Saidi, MD,* Joseph Carvajal, MD,†
gnès Lehmann,† Marc Lambert, MD,* Jean-Louis Bonnet, MD,* Marie-Christine Alessi, MD, PHD†
arseille, France
OBJECTIVES We analyzed the benefit of a 600-mg clopidogrel loading dose on platelet reactivity and
clinical outcomes after stenting for non–ST-segment elevation acute coronary syndrome
(NSTE ACS).
BACKGROUND High post-treatment platelet reactivity (HPPR  adenosine diphosphate 10 mol · l1
[ADP]–induced platelet aggregation 70%) is a marker for low responders to dual
antiplatelet therapy with increased risk of recurrent cardiovascular (CV) events after stenting
for NSTE ACS.
METHODS A total of 292 consecutive NSTE ACS patients undergoing coronary stenting were included
and randomly received a 300-mg (n  146) or 600-mg (n  146) loading dose of clopidogrel
at least 12 h before percutaneous coronary intervention. A single post-treatment blood sample
was obtained before percutaneous coronary intervention to analyze maximal intensity of
ADP-induced platelet aggregation and platelet surface expression of P-selectin. One-month
follow-up CV events were recorded.
RESULTS The ADP-induced platelet aggregation and expression of P-selectin were significantly lower
in patients receiving 600 mg than in those receiving 300 mg (mean SD: 50 19% vs. 61 
16%, p  0.0001 and 0.38  0.24 arbitrary units vs. 0.60  0.40 arbitrary units; p  0.0001
respectively). Persistence of HPPR was less common in patients receiving 600 mg than in
those receiving 300 mg (15 vs. 25%, p 0.03). During the 1-month follow-up, 18 CV events
(12%) occurred in the 300-mg group versus 7 (5%) in the 600-mg group (p  0.02); this
difference was not affected by adjustment for conventional CV risk factors (p  0.035).
CONCLUSIONS In NSTE ACS patients undergoing coronary stenting, a 600-mg loading dose of clopidogrel
shows its benefit on platelet reactivity and clinical prognosis. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.0491339–45) © 2006 by the American College of Cardiology Foundation
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dlatelet reactivity plays a key role in the pathogenesis of
schemic complications after stenting for non–ST-segment
levation acute coronary syndrome (NSTE ACS). Accord-
ngly, platelet inhibition with a thienopyridine (clopidogrel)
as significantly reduced recurrent ischemic events in this
linical setting, and in combination with aspirin, clopidogrel
s now the treatment of choice for preventing stent throm-
osis (1) and reducing major adverse cardiovascular (CV)
vents after NSTE ACS (2,3). Nevertheless, ischemic
vents still occur. These recurrences involve a complex and
ultifactorial process, and low response to antiplatelet
herapy could be a major factor. Indeed numerous biological
tudies, essentially based on adenosine diphosphate (ADP)-
nduced platelet aggregometry, have reported interindi-
idual variability in platelet response to clopidogrel (4–8);
hese studies identified patients who did not achieve platelet
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upported by the Assistance Publique Hôpitaux de Marseille.i
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ccepted June 12, 2006.nhibition as low responders or “resistants.” However, anti-
latelet effect monitoring would be of limited relevance in
he absence of clinical implication. Precisely, as has been
hown for aspirin (9), a relationship between clopidogrel
esistance and recurrence of clinical outcomes has been
eported in several studies (7,10–13). We previously showed
hat in NSTE ACS patients undergoing coronary stenting,
he high post-treatment platelet reactivity (HPPR) (maxi-
al intensity of ADP 10 mol · l1 induced platelet aggre-
ation 70%) identified low responders to dual antiplatelet
herapy (aspirin and clopidogrel) at higher risk of CV events
uring a 1-month follow-up (14). According to these
esults, other therapeutic approaches should be considered
or these low-responder patients, such as higher doses or
lternative treatments. Currently, the 300-mg loading dose
f clopidogrel given at least 6 h before the procedure
epresents the conventional antiplatelet regimen before
ercutaneous coronary intervention (PCI). A higher loading
ose of clopidogrel has already shown its capacity to
mprove platelet reactivity after treatment in healthy volun-
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Platelet Reactivity and Acute Coronary Syndrome October 3, 2006:1339–45eers and patients (15–21) with an earlier and stronger
nhibition of ADP–induced platelet activation than the
00-mg loading regimen, and its efficiency for the preven-
ion of periprocedural infarction in stented patients (22).
owever, to the best of our knowledge, no study has ever
ested both platelet parameters and clinical outcomes after
ncreasing the loading dose of clopidogrel, especially in
igh-risk groups such as stented NSTE ACS patients.
herefore, we conducted a randomized and prospective
tudy to evaluate the benefit of a higher loading dose of
lopidogrel on platelet aggregation and recurrent ischemic
vents for NSTE ACS patients undergoing coronary
tenting.
ETHODS
tudy population. Consecutive patients admitted for
STE ACS to the Department of Cardiology of the
imone hospital between June 2004 and October 2005 were
ligible for this prospective study if they had undergone
uccessful coronary stenting. We defined NSTE ACS as
linical symptoms compatible with acute myocardial isch-
mia within 12 h before admission and at least 1 of the
ollowing: a new finding of ST-segment depression 0.05
V, transient (20 min) ST-segment elevation 0.1 mV,
-wave inversion0.3 mV in at least 2 leads, elevated levels
f cardiac markers or coronary disease as documented by a
istory of catheterization, revascularization, or myocardial
nfarction. The exclusion criteria were a history of bleeding
iathesis, persistent ST-segment elevation ACS, New York
eart Association functional class IV, PCI or coronary
ypass grafting3 months, contraindications to antiplatelet
herapy, platelet count 100 g · l1, creatinine clearance
25 ml · min1, and use of glycoprotein IIb/IIIa inhibitors
efore the procedure. Patients were randomly assigned to
eceive a 300-mg or 600-mg loading dose of clopidogrel at
east 12 h before stenting. All patients received aspirin 160
g daily after a loading dose of 250 mg administered at least
2 h before stenting. The PCI was performed within 48 h
fter admission. For all patients, anticoagulation was begun
efore PCI in the intensive care unit and performed with
Abbreviations and Acronyms
ADP  adenosine diphosphate
CREDO  Clopidogrel for Reduction of Events
During Observation
CV  cardiovascular
HPPR  high post-treatment platelet reactivity
NSTE ACS  non–ST-segment elevation acute coronary
syndrome
PCI  percutaneous coronary intervention
PCI-CURE  Percutaneous Coronary Intervention-
Clopidogrel in Unstable Angina to
Prevent Recurrent Events
PRP  platelet-rich plasma
ST  stent thrombosisow-molecular-weight heparin (enoxaparin), or unfraction- rted heparin in patients over 75 years old or with renal
nsufficiency. The study protocol was approved by the
nstitutional ethics committee of our institution, and pa-
ients gave written informed consent for participation.
lood samples. Blood samples for testing platelet reactiv-
ty were drawn in the catheterization laboratory from a 6-F
rterial sheath before the PCI at least 12 h after the loading
ose of clopidogrel and aspirin, and before administration of
irofiban if needed. The initial first millimeters of blood
ere discarded to avoid platelet activation induced by needle
uncture, and blood was immediately collected in Vacu-
ainer tube containing 3.8% trisodium citrate, filled to
apacity, and then inverted 3 to 5 times for gentle mixing
nd drawn immediately to the hemostasis laboratory.
latelet aggregation. The blood–citrate mixture was cen-
rifuged at 120 g for 5 min. The resulting platelet-rich
lasma (PRP) was kept at room temperature for use within
h. The platelet count was determined in the PRP sample
nd adjusted to 2.5  108 ml1 with homologous platelet-
oor plasma. Platelets were stimulated with ADP (10
mol · l1), and aggregation was assessed with a PAP4
ggregometer (Biodata Corporation, Wellcome, Paris,
rance). Aggregation was expressed as the maximal percent-
ge change in light transmittance from baseline with
latelet-poor plasma as a reference. Here we report data on
aximal intensity of platelet aggregation with ADP con-
entrations. The coefficient of variation of maximal intensity
f platelet aggregation with ADP was 6.5%.
low cytometry. The surface expression of the internal
lpha-granule membrane protein P-selectin expressed on
he surface of ADP activated platelets was determined by
ow cytometry with monoclonal antibody. The following
ntibodies were used: anti-CD62P (Beckman Coulter, Ful-
erton, California) and antimouse goat immunoglobulin
Ig)G FITC (antimouse goat IgG labeled with fluorescein
sothiocyanate; Beckman Coulter). Briefly, PRP was diluted
:10 in tyrode albumin buffer (0.25 108 ml1) and gently
ixed. Both antibody anti-CD62P (10 l of dilution 1:10)
nd ADP (final concentration 10 mol · ml1) or tyrode
lbumin buffer were added to 10 l of diluted PRP. After
ncubation in the dark at room temperature for 15 min, 10
l of antimouse goat IgG FITC (diluted 1:10) were added
nd again incubated in the dark at room temperature for 15
in. Scatter signals and fluorescence intensity were ana-
yzed on a EPICS XL-MCL flow cytometer (Beckman
oultronics, Margency, France). The light-scattering prop-
rties projected on a scattergram identified the platelet
luster. Fluorescence intensity was expressed on individual
ytohistograms, with the region of interest limited to the
latelet cluster. The mean channel fluorescence intensity
as used as an index of antibody binding and P-selectin
urface expression.
latelet function end point. We analyzed the mean max-
mal intensity of ADP-induced platelet aggregation in both
roups, receiving 300 mg or 600 mg of clopidogrel. We also
eported the rate of persistence of HPPR, defined as
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October 3, 2006:1339–45 Platelet Reactivity and Acute Coronary SyndromeDP-induced platelet aggregation 70%, in both groups.
inally, we studied the expression of P-selectin to evaluate
latelet activation.
linical end point. The clinical end point included the
ollowing CV events: CV death, acute or subacute stent
hrombosis, recurrent ACS, and stroke. Follow-up events
ere prospectively assessed by clinical visit. An ACS was
efined by the presence of symptoms compatible with
ecurrent ischemia needing new hospitalization and coro-
ary angiography, ischemic stroke was defined as a new
ocal neurologic deficit without bleeding on tomodensito-
etry and confirmed by a neurologist that as occurring
ithin 1 month of PCI. Drug therapy compliance was
ssessed. Occurrence of major bleeding defined as intracra-
ial bleeding or clinically overt bleeding associated with a
ecrease in hemoglobin of 5 g · dl1, according to the
hrombolysis in Myocardial Infarction criteria (23), were
eported. The treating physician and the investigators who
valuated the clinical end points were blinded to the results
f the platelet testing.
tatistical analysis. Statistical analysis was performed with
he SAS Software (version 9.01; SAS Institute Inc., Cary,
orth Carolina). Continuous variables are expressed as
ean  SD. Categorical variables are expressed as
requencies and percentages. For continuous variables,
ean levels were compared between individuals with 300
g and 600 mg of by analysis of variance, and for
ategorical variables, proportions were compared by chi-
quare test. Variables with a skewed distribution were
og- or square root-transformed before analysis. The
ffect of the loading dose of clopidogrel on CV event was
Table 1. Baseline Characteristics of the Patien
Characteristics 300 mg
Age, yrs 64.2
Men, n (%) 11
Hypertension, n (%) 8
Diabetes mellitus, n (%) 4
Current smoker, n (%) 5
Dyslipidemia, n (%) 8
Previous ACS, n (%) 6
Familial history, n (%) 4
Body mass index, kg/m2 26.6
Medications
Statins, n (%) 8
Beta-blocker, n (%) 7
Diuretics, n (%) 2
Troponin, n (%) 3
ST-segment changes, n (%) 3
Left ventricular ejection fraction, % 56
Creatinine, mol·l1 95
Procedural features
Total stent length, mm 18
Tirofiban, n (%) 5
Anticoagulation
LWMH 9
UFH 5
Values are mean  SD for quantitative variables and n (%) f
on log-transformed values.
ACS  acute coronary syndrome; LMWH  low molecular werformed using logistic regression analysis. Three mod-
ls were considered successively: Model 1: after adjustment
or age and gender; Model 2: additionally adjusted for
otential confounders such as conventional CV risk factors,
reatment, and inflammatory parameters; Model 3: addi-
ionally adjusted for HPPR.
ESULTS
atient characteristics. From June 2004 to October 2005,
total of 387 NSTE ACS patients who fulfilled the
nrollment criteria were randomized to a 300-mg (n 192)
r 600-mg (n  195) loading dose of clopidogrel. After
oronary angiography, 95 patients who did not receive
uccessful angioplasty were excluded from the study (72
ere treated medically, 20 with elective bypass surgery and
with failed PCI). Of the 292 study patients with successful
oronary stenting, 146 were randomized to a 300-mg and
46 to a 600-mg loading dose of clopidogrel. Demographic
ata of the studied population are summarized in Table 1.
he demographic, clinical, and therapeutic parameters were
imilar in the 300-mg and 600-mg groups. The mean time
etween the loading dose of clopidogrel and blood sampling
as 18.4 2.6 h and 19.2 2.7 h, respectively, for patients
eceiving 300 mg or 600 mg (p  0.56). All patients
eceived 75 mg clopidogrel and 160 mg aspirin during the
-month follow-up period.
latelet parameters. PLATELET AGGREGATION. We ana-
yzed post-treatment platelet reactivity using the maximal
ntensity of ADP-induced platelet aggregation. The distri-
ution of this response was consistent with a normal
cording to the Loading Dose of Clopidogrel
146) 600 mg (n  146) p Value
.3 65.2  12.0 0.48
) 108 (73) 0.34
) 81 (56) 0.67
) 48 (33) 0.45
) 76 (52) 0.06
) 79 (55) 0.81
) 66 (45) 0.90
) 53 (36) 0.62
6 27.3  7.2 0.10
) 88 (61) 0.90
) 62 (42) 0.24
) 24 (16) 1.00
) 30 (21) 0.27
) 36 (25) 0.58
55  11 0.54
113  89 0.06
17  3 0.74
) 48 (33) 0.75
) 99 (68) 0.78
) 47 (32) 0.81
litative variables. For skewed variables, tests were performedts Ac
(n 
 10
4 (79
4 (58
2 (29
9 (40
1 (56
5 (44
9 (34
 3.
7 (60
1 (49
4 (16
8 (26
2 (22
 9
 21
 4
1 (35
5 (65
1 (35
or quaeight heparin; UFH  unfractionated heparin.
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Platelet Reactivity and Acute Coronary Syndrome October 3, 2006:1339–45ell-shaped distribution. Maximal intensity of ADP-
nduced platelet aggregation was significantly lower in
atients who received a 600-mg loading dose of clopidogrel
han in those who received 300 mg (mean SD: 50 19%
s. 61  16%, p  0.0001) (Fig. 1).
The persistence of HPPR was less common in patients
eceiving a 600-mg loading dose of clopidogrel (n  22,
5%) than in those receiving 300 mg (n  36, 25%, p 
.04).
XPRESSION OF P-SELECTIN. The mean expression of
-selectin was significantly lower in patients receiving a
00-mg loading dose of clopidogrel than in those receiving
00 mg (0.38  0.24 arbitrary units vs. 0.60  0.40
rbitrary units; p  0.0001) (Fig. 2).
linical outcomes. One-month follow up was completed
n all patients. Twenty-five CV events (8.5%) occurred in
he whole population during follow-up. Recurrent ischemic
vents occurred more frequently in the 300-mg group than
n the 600-mg group: 18 (12%) and 7 (5%), respectively
p  0.02). This difference was not affected by adjustment
or potential confounders such as age, gender, CV risk
actors, troponin elevation, ST-segment changes, left ven-
ricular ejection fraction, or tirofiban use (p  0.035).
istribution of the CV events was 15 hospitalizations for
ecurrent ACS (2 acute stent thrombosis), 2 strokes, and 1
V death for the 300-mg group; and 6 hospitalizations for
ecurrent ACS (1 acute stent thrombosis) and 1 stroke for
he 600-mg group (Figs. 3 and 4).
igure 1. Maximal intensity of adenosine diphosphate (ADP)-induced
latelet aggregation in the 300-mg and 600-mg groups.igure 2. Mean fluorescence intensity of P-selectin expression in the
00-mg and 600-mg groups. AU  arbitrary units.
F
aIn both groups, HPPR contributed to recurrence of CV
vents after adjustment for age and gender: (OR [odds ratio]
.93 [95% confidence interval (CI) 3.19 to 30.90] and OR 
3.16 [95% CI 4.89 to 381.10], respectively, for 300-mg and
00-mg groups). In the 300-mg group, 67% (n  12) of
linical events occurred in patients with HPPR, and 85%
n  6) in the 600-mg group.
When including both clopidogrel loading doses and
ersistence of HPPR as well as potential confounders in a
ogistic regression analysis, only persistence of HPPR re-
ained independently associated with CV events (OR 
3.82 [95% CI 5.30 to 36. 04], p  0.0001). No patient in
ither group had postprocedural major bleeding or required
ransfusions.
ISCUSSION
ompared with the 300-mg clopidogrel loading dose, our
tudy shows that a 600-mg bolus allows a superior antiplate-
et effect and improves clinical outcomes in patients under-
oing coronary stenting for NSTE ACS. Clopidogrel is an
ntiplatelet agent inhibiting the ADP receptor. Because of
ts safety profile and the results of clinical trials, clopidogrel
as become the standard treatment for ACS and stenting
1–3). Two large studies in patients with ACS have shown
hat pretreatment with clopidogrel may have beneficial
ffects. This pretreatment was given a mean of 6 days before
ntervention in the observational PCI-CURE (Percutane-
us Coronary Intervention—Clopidogrel in Unstable An-
igure 3. Clinical outcomes according to loading dose of clopidogrel.
CS  acute coronary syndrome; CV death  cardiovascular death;
VE  cardiovascular events; ST  stent thrombosis.igure 4. Kaplan-Meier analysis for 30-day cardiovascular (CV) events
ccording to loading dose of clopidogrel. Log-rank  9.24, p  0.0024.
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October 3, 2006:1339–45 Platelet Reactivity and Acute Coronary Syndromeina to Prevent Recurrent Events) (3) and 3 to 24 h in the
andomized CREDO (Clopidogrel for the Reduction of
vents During Observation) trial (24). Accordingly, current
ommon clinical practice consists of pretreatment with a
00-mg loading dose of clopidogrel at least 6 h before the
rocedure in patients with ACS, as well as in those
ndergoing elective intervention. Despite the routine use of
ual antiplatelet therapy with loading dose of clopidogrel,
ecurrent ischemic events occurred and antiplatelet respon-
iveness involvement emerged in numerous studies as a
otential responsible factor.
Clopidogrel resistance was initially supported by several
iological studies usually based on ADP-induced platelet
ggregation, which emphasized high interindividual vari-
bility of in vitro platelet response to standard dose of
lopidogrel (4–8). Mechanisms involved are not yet clear;
ariability in intestinal absorption and the hepatic cyto-
hrome P450 3A4 activity were reported as important
actors (9). Moreover, several factors could modulate clopi-
ogrel antiplatelet effectiveness. Indeed, a recent study by
araff et al. (25) showed that the benefit of dual antiplatelet
herapy with aspirin and clopidogrel was especially pro-
ounced in smokers, probably because smoking increases
latelet reactivity and smokers have poor outcomes after
CI compared with nonsmokers. In the present study, there
as a trend toward an increased prevalence of smokers in
he 600-mg group. It suggests that the benefit of a higher
oading dose could have been greater without this difference
etween the 300-mg and 600-mg groups. The clinical
elevance of the clopidogrel resistance has already been
eported in several retrospective studies showing a correla-
ion between platelet parameters and stent thrombosis
7,10–12). Only 2 prospective studies evaluated the rela-
ionship between clopidogrel responsiveness and recurrent
schemic events after ACS (13,14). Nevertheless, the lack of
standard definition of resistance as well as the lack of a
tandard diagnostic modality has hampered the field in
dentifying and treating this clinical entity.
Consequently, some investigators suggested to study
ost-treatment platelet reactivity rather than antiplatelet
esponsiveness as a risk marker of clinical outcomes (14).
oreover, recent studies (14,26) proposed the ADP-
nduced post-treatment platelet aggregation as a means of
valuating the response both to clopidogrel and to aspirin.
o determine a useful measurement of platelet reactivity in
aily clinical practice, we use one single blood sample
esting ADP-induced post-treatment platelet aggregation.
e identified HPPR (ADP-induced platelet aggregation
70%), in spite of dual antiplatelet therapy with a 300-mg
oading dose of clopidogrel as a risk marker of recurrent
schemic events (14). Therefore, the results of the present
tudy confirmed that the HPPR have a predictive value for
ecurrent ischemic events in both the 300-mg and the
00-mg groups. Moreover, the multivariable analysis
howed that the HPPR was a better predictor of clinical
utcomes than the 300-mg or 600-mg loading dose, sug- desting that the benefit of higher clopidogrel loading dose
n clinical prognosis is directly linked to the decreasing
ersistence of HPPR. These supplementary data seem to
alidate the use of this marker in daily clinical practice to
dentify “high-risk” patients with persistent HPPR.
The dose of 300 mg of clopidogrel derives from dose-
nding data on healthy volunteers; however, patients with
oronary artery disease may have enhanced platelet reactivity
s compared with healthy individuals, and so probably
equire more aggressive platelet inhibition. Indeed, in an
nvironment of high thrombin activity, it has been shown
hat clopidogrel might not reduce enough platelet activity
ecause it did not inhibit the platelet aggregation and
egranulation after stimulation with the thrombin-related
ctivating peptide (27). Moreover, a study by Soffer et al.
28) has correlated the level of angina class with platelet
nhibition by clopidogrel and found that patients with a
igher Braunwald angina class had lower inhibition of
latelet aggregation. The standard dose of 300 mg is
robably not as efficient during ACS as it has been shown in
ealthy subjects. Plasma concentration of the active drug
nfluences platelet aggregation after first administration in a
ose-dependent manner (29). Thus, a more rapid and
ntense platelet suppression represents the rationale for
retreatment with a 600-mg loading dose of clopidogrel.
everal studies have shown a benefit of higher clopidogrel
oading on platelet aggregation with a decreased rate of
onresponders and platelet reactivity (15–21), and a previ-
us study showed a benefit of 600 mg of clopidogrel
ompared with the standard 300-mg regimen on the inci-
ence of periprocedural elevation of markers of myocardial
ecrosis (22). Even more recently, a dose of 900 mg was
ested, although this did not seem to produce any more
ctive metabolite or inhibition of platelet function than the
00-mg dose (20). In the present study, we showed both a
iological and a clinical benefit of a higher loading dose of
lopidogrel. Moreover, in our study, a higher loading dose
f clopidogrel was not associated with important bleeding
omplications. Elsewhere, other antithrombotic strategies
ay be useful for these “antiplatelet nonresponders” at high
isk of recurrent ischemic events. First, use in the peripro-
edural period of GPIIb/IIIa antagonist infusion would be
eneficial in these patients. Indeed, a recent study has
hown the lower clinical event rate after administration of
bciximab in higher-risk NSTE ACS patients in spite of a
00-mg loading dose of clopidogrel (30). Secondly, the
mergence of new ADP-antagonists such as prasugrel
ould probably be helpful in this clinical setting. Clinical
tudies are required to validate these hypotheses.
tudy limitations. It should be mentioned that the sample
ize of the present study is relatively small, and therefore
oes not allow for definitive conclusions. In our study,
iming between the loading dose of clopidogrel and PCI was
2 to 24 h. However, a recent study by Steinhubl et al. (31)
rom the CREDO study showed that a 300-mg loading
ose had no effect if administrated 15 h before PCI, and
t
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Platelet Reactivity and Acute Coronary Syndrome October 3, 2006:1339–45hat the effect was not optimal until approximately 24 h
efore PCI. Moreover, in the ISAR REACT (Intracoro-
ary Stenting and Antithrombotic Regimen Rapid Early
ction for Coronary Treatment) study with a 600-mg
oading dose, no relationship was found between the dura-
ion of pretreatment (2 to 24 h) and clinical events (32). The
esign of our study could partially explain the benefit of a
igher loading dose for patients pretreated with a 300-mg
oading between 12 to 24 h before PCI. Finally, the clinical
ombined end point chosen in our study is obviously
ebatable, especially because the usually used periprocedural
nfarction, defined with elevation of creatine kinase-Mb or
roponin, was not included.
onclusions. Our study showed that pretreatment with a
00-mg loading dose of clopidogrel given before PCI for
STE ACS is safe and, as compared with the 300-mg dose,
mproves periprocedural platelet inhibition and reduces
ecurrent ischemic events. The low risk and efficiency of this
harmacological regimen may support its routine use in
CS patients before PCI, as recently evoked in the Euro-
ean Society of Cardiology (33) and American College of
ardiology/American Heart association guidelines (34), but
arger clinical studies are required.
eprint requests and correspondence: Dr. Marie-Christine
lessi, INSERM, UMR 626 Marseille, F-13385 France. E-mail:
arie-Christine.Alessi@medecine.univ-mrs.fr.
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